Advertisement

Advertisement

In the Literature

New Agents That Improve Efficacy Can Also Increase Morbidity and Treatment-related Mortality

Charlotte Bath  /  September 1, 2012

Newly approved anticancer drugs that lead to improvements in efficacy can also lead to increased morbidity and treatment-related mortality, according to a study in the Journal of Clinical Oncology. The investigators conducted a meta-analysis of 38 randomized controlled trials evaluating agents appro...

Breast Cancer

Taxane-induced Neuropathy Does Not Correlate with Improved Outcomes in Operable Breast Cancer

Charlotte Bath  /  September 1, 2012

An analysis of 4,554 patients who received adjuvant weekly paclitaxel and other taxane-based regimens in the E1199 trial “demonstrated that taxane-induced peripheral neuropathy does not correlate with improved outcomes in patients with operable breast cancer,” investigators reported in the Journal o...

Kidney Transplant Recipients Switching to Sirolimus Had Lower Risk of Secondary Squamous Cell Carcinomas

Charlotte Bath  /  September 1, 2012

Kidney transplant recipients with at least one previous cutaneous squamous cell carcinoma decreased their risk of developing new cutaneous squamous cell carcinomas by switching from calcineurin inhibitors (cyclosporine or tacrolimus) to sirolimus (Rapamune) in a multicenter phase III study. New squa...

Lymphoma

Intensified Chemotherapy with R-ACVBP Improves Survival in Younger Patients with Diffuse B-cell Lymphoma

The ASCO Post  /  January 1, 2012

Compared with standard R-CHOP (rituximab [Rituxan], doxorubicin, cyclophosphamide, vincristine, and prednisone), intensified immunochemotherapy with R-ACVBP (dose-intensive rituximab, doxorubicin, cyclophosphamide, vindesine [not available in U.S.], bleomycin, and prednisone) significantly improves ...

Gastrointestinal Cancer

Adjuvant Chemotherapy with S-1 Improves Survival in Stage II/III Gastric Cancer

The ASCO Post  /  January 1, 2012

Postoperative adjuvant therapy with the oral fluoropyrimidine derivative S-1 improved overall survival and relapse-free survival in patients with stage II or III gastric cancer who had D2 gastrectomy. Five-year survival rates in the phase III study were 71.7% for patients in the S-1 group vs 61.1% i...

Skin Cancer

Physician-based Screening Leads to the Detection of Thinner Melanomas with More Favorable Prognosis

The ASCO Post  /  January 1, 2012

Physician-based screening leads to detection of thinner melanomas that were less likely to have negative prognostic attributes such as ulceration and dermal mitosis, according to a retrospective review of patient records and biopsy logs from 394 patients diagnosed with cutaneous melanoma. The result...

Lymphoma

After Complete Response to Chemotherapy, IFRT Improves Event-free Survival in Hodgkin Lymphoma

Charlotte Bath  /  July 1, 2012

Final data from the Children’s Cancer Group (CCG) trial evaluating low-dose involved-field radiation therapy (IFRT) for patients with Hodgkin lymphoma achieving a complete response after chemotherapy show that at a median follow-up of 7.7 years, IFRT produced a statistically significant improvement ...

Thyroid Cancer

Wide Variation in Use of Radioactive Iodine for Thyroid Cancer

The ASCO Post  /  September 15, 2011

The proportion of patients with well-differentiated thyroid cancer who received radioactive iodine following total thyroidectomy increased significantly since 1990, and there is wide variation in the use of adjuvant radioactive iodine, according to a study in the Journal of the American Medical Asso...

Multiple Myeloma

Subcutaneous Bortezomib Offers Improved Safety Profile for Treating Patients with Relapsed Multiple Myeloma

The ASCO Post  /  June 15, 2011

Subcutaneous administration of bortezomib (Velcade) was comparably efficacious to intravenous administration in a phase III trial in patients with relapsed multiple myeloma, but the SC route “seemed to have an improved systemic safety profile compared with intravenous delivery,’’ investigators repor...

Thyroid Cancer

Obese Patients at Higher Risk of Aggressive Thyroid Tumors

Charlotte Bath  /  July 1, 2012

Obese patients present with more advanced and more aggressive forms of papillary thyroid cancer and should be screened for thyroid cancer with sonography, which is more sensitive in detecting thyroid cancer than physical examination alone, according to a study published online in the Archives of Sur...

Lung Cancer

Nearly 800,000 Lung Cancer Deaths Averted during 1975–2000 Due to Decline in Smoking Rates

The ASCO Post  /  May 1, 2012

The cumulative impact of changes in smoking behavior that started in the mid-1950s averted approximately 795,851 U.S. lung cancer deaths, 552,574 among men and 243,277 among women from 1975 to 2000, according to a report in the Journal of the National Cancer Institute. The researchers also estimated...

Prostate Cancer

Androgen Deprivation plus Radiotherapy Increases Survival in Men with Localized Prostate Cancer

The ASCO Post  /  September 15, 2011

Adding short-term androgen-deprivation therapy to radiotherapy “conferred a modest but significant increase in the 10-year rate of overall survival, from 57% to 62%,” in men with localized prostate cancer enrolled in Radiation Therapy Oncology Group (RTOG) trial 94-08. “This increase was accompanied...

Lung Cancer

Identifying Genetic Factors That Predict Response to Chemotherapy in NSCLC

The ASCO Post  /  September 1, 2011

A genetic variation in the chemokine-like receptor 1 (CMKLR1) gene was statistically significantly associated with poor overall survival in patients with non–small cell lung cancer (NSCLC) who were treated with platinum-based chemotherapy with or without radiation. The variation was identified by a ...

Colorectal Cancer

Adding Cetuximab to Adjuvant Therapy with Modified FOLFOX6 Does Not Improve Survival

The ASCO Post  /  May 1, 2012

Adding cetuximab (Erbitux) to adjuvant treatment with mFOLFOX6, the modified sixth version of FOLFOX (leucovorin, fluorouracil, oxaliplatin) did not improve disease-free survival among patients with resected stage III colon cancer, even those with wild-type KRAS, according to a phase III study in th...

Breast Cancer

Comorbidities Can Be as Important as Stage in Predicting Breast Cancer Survival in Older Patients

The ASCO Post  /  September 15, 2011

Comorbidities can be as important as stage in predicting survival among older women with breast cancer, according to a study in the Journal of the National Cancer Institute. While previous studies have combined comorbidities into a summary measure or comorbidity index, the current study assessed the...

Prostate Cancer

Androgen Deprivation Therapy plus Radiotherapy Increases Survival in Men with Localized Prostate Cancer

The ASCO Post  /  September 1, 2011

The addition of short-term androgen deprivation therapy to radiotherapy for men with stage T1b, T1c, T2a, or T2b prostate adenocarcinoma and a prostate-specific antigen (PSA) level of 20 ng/mL or less “conferred a modest but significant increase in the 10-year rate of overall survival, from 57 to 62...

Breast Cancer

Patients with HER2-positive Breast Cancer Benefit from Trastuzumab plus Chemotherapy

The ASCO Post  /  September 15, 2011

Adding trastuzumab (Herceptin) to standard anthracycline/taxane–based chemotherapy continued to produce disease-free and overall survival benefits in patients with HER2-positive breast cancer enrolled in the North Central Cancer Treatment Group (NCCTG) N9831 and the National Surgical Adjuvant Breast...

Bladder Cancer

Neoadjuvant Chemotherapy with CMV Improves Outcome for Invasive Bladder Cancer

The ASCO Post  /  September 1, 2011

Long-term results from a phase III trial show that neoadjuvant chemotherapy with CMV (cisplatin, methotrexate, and vinblastine) improves the outcome for patients with muscle-invasive urothelial cancer of the bladder treated by cystectomy and/or radiotherapy. “Three cycles of CMV before cystectomy o...

Prostate Cancer

Death Rates Significantly Reduced for Men Having Radical Prostatectomy vs Watchful Waiting

The ASCO Post  /  June 15, 2011

Estimated 15-year results from the Scandinavian Prostate Cancer Group Study (SPCG-4) show that men diagnosed with early prostate cancer and randomly assigned to radical prostatectomy continued to have significantly reduced rates of death from prostate cancer, death from any cause, and risk of metast...

Risk Reduction for Patients with Multiple Primary Cancers

Charlotte Bath  /  November 15, 2012

The number of patients with multiple primary cancers is increasing so that second malignant neoplasms now represent approximately 16%, or 1 in 6 cancers reported to the Surveillance, Epidemiology, and End Results (SEER) Program. While some second malignant neoplasms are treatment-related, others are...

Breast Cancer

Unexpected Results May Push Breast Cancer Research toward More Productive Approaches

The ASCO Post  /  September 15, 2011

Two recent articles on breast cancer prognostic factors in the Journal of Clinical Oncology “do not jibe with accepted—and profoundly influential—notions of malignant progression,” according to an editorial accompanying the articles in the Journal of Clinical Oncology. One of the articles found that...

Colorectal Cancer

Surgical Site Infections after Colectomy More Likely in Obese Patients

The ASCO Post  /  September 1, 2011

Obese patients appear to have a significantly increased risk of developing a surgical site infection after segmental or total colectomy for colon cancer, diverticulitis, or inflammatory bowel disease, and the presence of infection increases the cost associated with the procedure, according to a repo...

Gynecologic Cancers

Adding Gemcitabine to Chemoradiation Improves Survival Outcomes for Locally Advanced Cervical Cancer

The ASCO Post  /  June 15, 2011

A phase III, open-label, randomized trial found that adding gemcitabine to concurrent cisplatin chemoradiotherapy and using gemcitabine as adjuvant chemotherapy with cisplatin improved survival outcomes in women with locally advanced cervical cancer. Toxicity was increased compared to standard treat...

Lung Cancer

Statistically Significant Decline in Lung Cancer Incidence and Death Rates among Women

The ASCO Post  /  June 15, 2011

More than a decade after lung cancer incidence and death rates began to decline in men, a statistically significant decrease in the rates are occurring among women. The Annual Report to the Nation on the Status of Cancer, 1975 to 2007, is the first to document these decreases, the report’s authors n...

Gynecologic Cancers
Geriatric Oncology

Elderly Patients with Ovarian Cancer Least Likely to Receive Chemotherapy

The ASCO Post  /  October 15, 2011

An analysis of data for 4,617 women aged 65 years or older diagnosed with epithelial ovarian cancer found that those in the oldest age group, 80 and up, were least likely to receive any chemotherapy. While 53% of patients 80 and older received no chemotherapy, the rate was less than half (22%) for t...

Kidney Cancer

Sunitinib-induced Hypertension May Be Efficacy Biomarker in Patients with Metastatic Renal Cell Carcinoma

The ASCO Post  /  June 15, 2011

A retrospective exploratory analysis of pooled efficacy data from more than 500 patients with metastatic renal cell carcinoma treated with sunitinib (Sutent) “support the hypothesis that hypertension may be a viable biomarker of antitumor efficacy in this patient population,” according to a report i...

Survivorship
Issues in Oncology

Risk of Cardiomyopathy in Childhood Cancer Survivors

Matthew Stenger and compiled by Liz Janetschek.  /  May 10, 2019

In a study reported in JAMA Oncology, Eric J. Chow, MD, MPH, and colleagues found that daunorubicin was associated with decreased cardiomyopathy risk vs doxorubicin among pediatric cancer survivors, with epirubicin being approximately isoequivalent to doxorubicin. Risk associated with the anthraqu...

Breast Cancer

Doxorubicin/Cyclophosphamide with Docetaxel Equally Effective in Combination or Sequentially

The ASCO Post  /  October 15, 2011

Five-year disease-free survival and overall survival rates were “indistinguishable” in patients with operable, node-positive, HER2-nonamplified breast cancer treated with the sequential or combination regimens of doxorubicin/cyclophosphamide (AC) and docetaxel (T). The Breast Cancer International Re...

Solid Tumors
Hepatobiliary Cancer

Adjuvant Capecitabine After Resection for Biliary Tract Cancer

Matthew Stenger and compiled by Liz Janetschek.  /  May 10, 2019

In the phase III BILCAP trial reported in The Lancet Oncology, John N. Primrose, FMedSci, and colleagues found evidence that adjuvant capecitabine may improve overall survival vs observation following surgery for patients with resected biliary tract cancer.  The open-label study included 447 pati...

Leukemia

Patients With Relapsed/Refractory CLL That Progresses Early on Ibrutinib Have Poor Outcomes

Charlotte Bath  /  June 25, 2015

Most patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who discontinued ibrutinib (Imbruvica) early “were difficult to treat and had poor outcomes,” according to a study of patients enrolled in four different clinical trials of ibrutinib, with or without rituximab (Rituxan), at Th...

Breast Cancer

Progression-free Survival in HER2-positive Metastatic Breast Cancer Improved with T-DM1 

Charlotte Bath  /  May 1, 2013

First-line treatment with ado-trastuzumab emtansine (T-DM1) “provided a significant improvement” in progression-free survival when compared to trastuzumab (Herceptin) plus docetaxel in a randomized phase II study among patients with HER2-positive metastatic or recurrent locally advanced breast cance...

Breast Cancer

Addition of Bevacizumab to Neoadjuvant Chemotherapy Increases Pathologic Complete Response Rate in HER2-negative Disease

The ASCO Post  /  March 1, 2012

Two studies reported in The New England Journal of Medicine showed that the addition of bevacizumab (Avastin) to neoadjuvant chemotherapy significantly increased the pathologic complete response rate in women with HER2-negative breast cancer. In one study, from the German Breast Group, the benefit w...

Breast Cancer

Comparing Therapies for Managing Hot Flashes in Women with Breast Cancer

The ASCO Post  /  October 15, 2011

In a double-blind, placebo-controlled trial, two often-prescribed treatments recommended in clinical guidelines for the management of hot flashes were found to be effective in managing hot flashes in patients with breast cancer. Patient-reported hot flash scores showed that venlafaxine, a selective ...

Colorectal Cancer

Venous Thromboembolism More Frequent after Open Colorectal Surgery than Post-laparoscopy

The ASCO Post  /  August 15, 2011

The risk of developing venous thromboembolism (VTE) may be nearly twice as high for patients undergoing open colorectal procedures as for those undergoing laparoscopic colorectal resections, according to a report in the Archives of Surgery. The authors also “identified malignancy, obesity, and conge...

Skin Cancer

Patients’ Desire for Rapid Notification of Skin Biopsy Results Leads to Preference for Phone Call Over Face-to-Face Visit

Charlotte Bath  /  June 25, 2015

Patients’ preference for how they receive biopsy results “has shifted from face-to-face visit to discussion over the telephone because of a desire for rapid notification,” according to a survey of 301 patients recruited at three different melanoma clinics. Although 67.1% of the patients preferred to...

Breast Cancer

Final Overall Survival Data Show Better Results With Higher Dose of Fulvestrant

Charlotte Bath  /  February 1, 2014

Among patients with locally advanced or metastatic estrogen receptor–positive breast cancer, fulvestrant (Faslodex) given at 500 mg “is associated with a 19% reduction in risk of death and a 4.1-month difference in median overall survival compared with fulvestrant 250 mg,” according to final results...

Leukemia

Bortezomib Added to Standard Induction Therapy Produced Encouraging AML Remission Rate  

Charlotte Bath  /  May 1, 2013

Adding bortezomib (Velcade) to standard daunorubicin and cytarabine induction chemotherapy for acute myeloid leukemia (AML) “resulted in an encouraging remission rate” in previously untreated older adults, according to results of Cancer and Leukemia Group B (CALGB/Alliance) study 10502. The frequenc...

Gynecologic Cancers

Nearly Identical Survival for Laparoscopy vs Laparatomy in Patients with Stage I/IIA Disease

The ASCO Post  /  March 1, 2012

Building on previously reported results that laparoscopic surgical management of uterine cancer is superior for short-term safety and length-of-stay endpoints, the Gynecologic Oncology Group reported small and lower than anticipated potential for increase risk of cancer recurrence with laparoscopy v...

Breast Cancer

Replacing Epirubicin with Docetaxel for Three Cycles Improved Outcomes for Node-positive Breast Cancer

The ASCO Post  /  October 15, 2011

Substituting docetaxel for epirubicin in the final three cycles of chemotherapy resulted in improvement in disease-free and overall survival in a trial among postmenopausal women with node-positive early breast cancer. Following complete excision, women enrolled in the Docetaxel Epirubicin Adjuvant ...

Colorectal Cancer

Endoscopic Excision May Be Viable Alternative to Surgical Resection of Large Colorectal Polyps

The ASCO Post  /  August 15, 2011

A retrospective review of 104 consecutive patients with large colorectal lesions, including 39 with carcinoma, found that “endoscopic excision of large colorectal polyps is a viable alternative to surgical resection in a select group of patients and can be performed safely with a good success rate.”...

Bladder Cancer

Mitomycin Gel for Low-Grade Upper Tract Urothelial Cancer

Matthew Stenger  /  May 25, 2020

On April 15, 2020, mitomycin gel was approved for the treatment of adult patients with low-grade upper tract urothelial cancer.1,2 Mitomycin gel is for pyelocalyceal use alone and not for intravenous, topical, or oral administration. Supporting Efficacy Data Approval was based on findings in the o...

Lung Cancer

No Survival Benefit With Avelumab vs Docetaxel in Platinum-Treated, Advanced, PD-L1–Positive NSCLC

Matthew Stenger and compiled by Liz Janetschek.  /  February 25, 2019

As reported in The Lancet Oncology by Fabrice Barlesi, MD, and colleagues, the phase III JAVELIN Lung 200 trial has shown no overall survival benefit with avelumab vs docetaxel in patients with platinum pretreated programmed cell death ligand 1 (PD-L1)–positive advanced non–small cell lung cance...

Skin Cancer
Immunotherapy

Neoadjuvant Combination Checkpoint Blockade in Advanced Melanoma

Matthew Stenger  /  February 10, 2019

Neoadjuvant combination checkpoint blockade showed activity among patients with high-risk stage III melanoma in a small study. However, a high incidence of side effects caused the trial to be closed early. These results were published by Rodabe N. Amaria, MD, Assistant Professor of Melanoma Medica...

Lung Cancer

Gefitinib or Erlotinib vs Chemotherapy in Advanced NSCLC

Matthew Stenger  /  May 10, 2017

In an individual patient data meta-analysis reported in the Journal of the National Cancer Institute, Lee et al found no difference in overall survival for first-line treatment with the first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib (Iressa) or erlotini...

Response to May 10 Cartoon

Lynne Lederman, PhD  /  June 25, 2015

As a medical writer specializing in oncology, an ASCO member, and someone who tries to build sensitivity to patients into all my work, I was concerned about the cartoon I saw in the May 10, 2015, issue of The ASCO Post. On page 46, there is a cartoon of someone being thrown off a cliff because he ha...

Lung Cancer

Some Lung Cancers Detected by Low-Dose CT in National Lung Screening Trial May Be Indolent

Charlotte Bath  /  February 1, 2014

More than 18% of all lung cancers detected by low-dose computed tomography in the National Lung Screening Trial (NLST) may be clinically insignificant. Overdiagnosis should be considered when describing the risks of [low-dose computed tomography] screening for lung cancer, according to a review of e...

Leukemia

Successful Salvage Treatment Possible in Some Patients Who Do Not Have a Transplant in First Remission 

Charlotte Bath  /  May 1, 2013

Among 3,919 patients with acute myeloid leukemia (AML) who did not undergo transplantation in first complete remission, 1,271 relapsed and 19% were successfully treated with salvage therapy, according to an analysis of three AML trials in the United Kingdom. This percentage can be improved with a tr...

Kidney Cancer

Significantly Longer Survival with Axitinib Compared to Sorafenib in Patients with Renal Cell Carcinoma

The ASCO Post  /  December 15, 2011

A phase III study comparing the vascular endothelial growth factor receptor (VEGFR) inhibitors axitinib and sorafenib (Nexavar) as second-line therapy in patients with metastatic renal cell carcinoma found that axitinib produced significantly longer progression-free survival. Published in The Lancet...

Colorectal Cancer

Hepatic Resection Remains Preferred Strategy for Colorectal Liver Metastases

The ASCO Post  /  October 15, 2011

Hepatic resection was shown to be superior to radiofrequency ablation (RFA) for the treatment of colorectal liver metastases, according to a model used to stimulate a randomized controlled trial. Researchers from the Hepatobiliary and Pancreatic Surgery Program at the Providence Portland Medical Cen...

Breast Cancer

Higher Risk of Recurrence for Triple-negative Breast Cancer after Modified Radical Mastectomy without Radiation

The ASCO Post  /  August 15, 2011

“The paucity of therapeutic options” for women with triple-negative breast cancer “emphasizes the urgent need to optimize the current locoregional management of patients with [triple-negative breast cancer] and reduce their risk of locoregional recurrence,” noted the authors of a Canadian study repo...

Advertisement

Advertisement



Advertisement